Open Access
Tableau I.
Résumé des principales études pivotales concernant le dupilumab dans la dermatite atopique.
| Nom de l’étude | N | Durée de l’étude (semaines) | Traitements topiques systématiques | Obtention de l’EASI 75 à 156 (%) | Obtention IGA 0/1 à 156 ou -2 points (%) | Survenue d’une conjonctivite | Références | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Dupilumab (2 doses) | Placebo | Dupilumab (2 doses) | Placebo | Dupilumab (2 doses) | Placebo | |||||
| Liberty ad solo 1 et 2 | 1 379 | 16 | non | 44-51 | 12-15 | 36-38 | 10 | 10 | 2,7 | [7] |
| Liberty ad chronos | 740 | 52 | oui | 64-69 | 23 | 38,7-39,2 | 12,4 | 15,8 | 5,4 | [8] |
| Liberty ad cafe | 325 | 16 | oui | 59,1-62,6 | 29,6 | NA | NA | 16,4-28 | 11,1 | [19] |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.